The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The injection, MariTide, helped patients with obesity lose up to 20% of their weight on average after a year, with no plateau ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

For the past year, there has been a huge buzz about the so-called "weight loss injection". This is supposed to help people ...

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...